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Abstract: The incidence, as well as the morbidity and mortality associated with heart failure (HF) continue to rise despite 
advances in diagnostics and therapeutics. A recent advance in the diagnostic and therapeutic approach to HF is the use of 
natriuretic peptide (NP) testing, including both B-type natriuretic peptide (BNP) and its amino terminal cleavage equiva-
lent (NT-proBNP). NPs may be elevated at an early stage among those with symptoms as well among those without. The 
optimal approach for applying NP testing in general populations is to select the target population and optimal cut off val-
ues carefully. Superior diagnostic performance is observed among those with higher baseline risk (such as hypertensives 
or diabetics). As well, unlike for acute HF, the cut off value for outpatient testing for BNP is 20-40 pg/mL and for NT-
proBNP it is 100-150 ng/L. In symptomatic primary care patients, both BNP and NT-proBNP serve as excellent tools for 
excluding HF based on their excellent negative predictive values and their use may be cost effective. Among those with 
established HF, it is logical to assume that titration of treatment to achieve lower NPs levels may be advantageous. There 
are several ongoing trials looking at that prospect. 
INTRODUCTION 
  Heart failure (HF) is a major and growing public health 
problem in the United States. The prevalence of HF in US is 
estimated around 5 million, and over 550 000 new cases are 
diagnosed with HF each year [1]. HF is the primary reason 
for 12 to 15 million office visits and 6.5million hospital days 
each year. The incidence, as well as the morbidity and mor-
tality associated with HF continues to rise despite advances 
in diagnostics and therapeutics [2]; this is in part due to the 
fact that ’salvage’ of patients with myocardial infarction is in 
part more successful, but also reflects the age-related in-
crease in the incidence of risk factors for HF, such as hyper-
tension. In addition, there is an equally large pool of patients 
with myocardial dysfunction but without apparent HF symp-
toms, or at worst, minor symptoms. This further complicates 
decision making, revealing inadequacy of clinical means 
alone to recognize HF [3].
  In addition to the diagnostic challenges, the timing and 
sequence of initiating treatments, gauging adequacy of ther-
apy and monitoring of therapy for adverse events are signifi-
cant challenges. Due to these factors the current care of pa-
tients with HF remains suboptimal [4] and many HF patients 
are hospitalized routinely for reasons that can be averted 
with good outpatient care [5] 
  A recent advance in the diagnostic and therapeutic ap-
proach to HF is the use of natriuretic peptide testing. Includ-
ing both B-type natriuretic peptide (BNP) and its amino ter-
minal cleavage equivalent (NT-proBNP), this class of bio-
marker has proven to be more useful than original expecta-
tions. This review will discuss recent advances in the use of 
natriuretic peptide testing to assist in the primary care recog-
nition and management of patients with suspected or proven 
HF. 
Heart Failure as a Progressive Disorder 
  HF is a progressive disorder accompanied with changes 
in left ventricular (LV) structure and geometry such that the  
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chamber dilates and/or hypertrophies and becomes more 
spherical—a process referred to as cardiac remodeling. This 
change further deteriorates myocardial function which in 
turn perpetuates the remodeling process. Cardiac remodeling 
generally precedes the development of symptoms (occasion-
ally by months or even years) and may continue despite 
treatment.  
  Several factors can accelerate the process of LV remodel-
ing, of these the activation of endogenous neurohormonal 
systems plays a vital role in cardiac remodeling and thereby 
in the progression of HF. Because natriuretic peptides (NPs) 
are produced in the heart, they may serve as a biological 
marker of LV remodeling and changes in circulating NPs 
may parallel the changes in LV structure [6-8]. 
BIOLOGY OF BNP AND NT-proBNP 
Synthesis, Release and Physiological Actions 
  Human BNP is synthesized as a pre-pro-peptide which is 
cleaved by endoprotease yielding a 108-amino-acid pro-
peptide(proBNP1-108) [9]. The propeptide is further cleaved 
by a furin- or corin-like endoprotease [10] to form biologi-
cally active BNP and inactive N-terminal proBNP. Both of 
these peptides circulate in human plasma [11]. 
  Multiple mechanisms induce the BNP gene, however, 
mechanical stretch is probably the most potent inducer of the 
BNP gene expression in cardiac myocytes [12]. In addition 
to myocytes, cardiac fibroblasts and the coronary vasculature 
have also been shown to express the BNP gene [13,14]. 
While BNP mRNA concentrations are higher in the atria 
than the ventricles [9], given the greater ventricular mass, 
total content of BNP mRNA is greater in the ventricle [15]; 
thus the ventricles are the main determinants of serum con-
centration of BNP under both physiologic and pathological 
conditions [16,17]. Besides stretch, additional stimuli for 
BNP release have been proposed including endotoxemia 
[18], hypoxia [19], and ischemia [20]. 
  While BNP may have several endocrine functions includ-
ing vasodilation, natriuresis, inhibition of the sympathetic 
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[21], it may also exhibits some autocrine and paracrine func-
tions, including regulation of myocyte growth, inhibition of 
fibroblast proliferation and extracellular matrix deposition, a 
cytoprotective anti-ischemic function, and influences on 
coronary endothelium and vascular smooth muscle prolifera-
tion and contractility [20, 22]. NT-proBNP, on the other 
hand is considered biologically inert [23], but its elevation 
nonetheless reflects activity of the BNP gene, and NT-
proBNP appears to provide comparable information to BNP 
in most circumstances. 
Circulating Concentrations of Natriuretic Peptides 
  Plasma concentrations of both NPs (BNP and NT-
proBNP) in healthy persons are much lower than in diseased 
states, are quite comparable to each other (unlike in disease 
states), and are more modified by physiologic factors includ-
ing age, gender and drugs than in the disease state. 
  NPs increase with age [24], probably related to the more 
frequent occurrence of systolic, and diastolic dysfunction 
and ventricular hypertrophy in the elderly, as well as the 
drop in renal function (requisite for clearance of both pep-
tides) seen with age [25]; NPs are higher in women [24], 
possibly due to estrogen levels in women in reproductive age 
[26] or effects of androgens in men, leading to lower values 
in males [27]. Circadian variation may be seen in BNP/NT-
proBNP concentrations, although these levels are small and 
clinically insignificant [28].  
  The effects of drugs on circulating NP concentrations are 
complex. Cardiovascular drugs with favorable effects on the 
neurohormonal system such as diuretics, angiotensin-con-
verting enzyme inhibitors, -adrenergic blockers, and spi-
ronolactone may lower NP values, in parallel with the im-
proved prognosis seen with treatment with these drugs [29-
52]. 
Biological Variability 
  The biological variation of NPs secretion must be con-
sidered when interpreting serial natriuretic peptide results. 
Biological variability refers to the expected day-to-day or 
week-to-week changes in NPs levels measured in apparently 
stable patients in response to physiologic changes such as 
changes vascular tone and filling pressures, without overt de-
stabilization[53-55], as well as possibly changes in clearance 
as well [56]. In addition, analytical imprecision and alternate 
splicing of BNP and/or NT-proBNP may also contribute to 
variability in circulating levels [57, 58]. 
  Recent studies suggest that in stable chronic heart failure 
patients, long-term intra-individual variation in natriuretic 
peptide levels is in the order of 30%, with a change of more 
than 23% likely to indicate a clinically significant change 
beyond background variation [59, 60]. NT-proBNP appears 
much less subject to wide biologic variability and appears 
relatively constant with variability that may be less than 10% 
[59].  
  In summary, considering biological variation, changes in 
BNP or NT-proBNP in the range of 25-30% likely reflects a 
“true” change, and may be interpretable in the context of 
therapeutic monitoring. While NT-proBNP appears less sub-
ject to the effects of biological variability than BNP, the sig-
nificance of this finding relative to the value for management 
of HF patients remains unclear. 
  Despite biological variability and conditions that modify 
NP levels, NPs remain potentially useful to discern a wide 
range of clinical conditions in HF patients. The applicability 
of natriuretic peptides is well accepted in inpatient care both 
in an emergency department setting as well as in a hospital-
ized patient with respect to diagnosis and prognosis, moreo-
ver, it has been found useful for screening, diagnosis and 
prognosis in outpatient care as well (Table 1). 
Table 1: Clinical Uses of Natriuretic Peptides. 
Screening for HF in high risk populations 
Prognostic evaluation in general population especially those with risk 
factor for heart disease. 
Differentiation of  HF from pulmonary conditions in dyspneic patients in
primary care  
Diagnosing HF in dyspneic patients in emergency department 
Determining HF severity, Prognosis  
Guiding HF therapy? 
CLINICAL APPLICATIONS OF NATRIURETIC 
PEPTIDES IN PRIMARY CARE 
Screening for Asymptomatic Ventricular Dysfunction  
  The widespread use of echocardiography for screening 
purposes in general population is limited by its costs and 
lack of availability in primary care settings. NPs levels may 
provide an important tool in screening asymptomatic patients 
with LV dysfunction as NPs may be elevated in these pa-
tients from conditions that predispose to clinical HF includ-
ing myocardial ischemia, inflammation, fibrosis, hypertro-
phy, and valvulopathy [19-22,65,66,]. The mechanisms of 
NPs elevation in these conditions at pre-clinical stage before 
accumulation of fluid and stretch of myocardium are thought
to be related to their potential role in modulation of ventricu-
lar structure/remodeling/fibrosis. [22,65-67]. As it has been 
proposed that their synthesis is transcriptionaly activated in 
response to the activation of rennin-angiotensin system and 
other neurohormonal pathways involved in heart failure 
  Screening for asymptomatic LV dysfunction is particu-
larly important as prevalence of asymptomatic LV systolic 
dysfunction alone is estimated from 0.9% to 12.9% [62], 
depending on baseline risk. Furthermore, among asympto-
matic patients early detection of cardiac remodeling or re-
lated structural and functional impairment may allow preven-
tive therapies to be initiated earlier delaying progression to 
HF [63, 64]. Moreover outcome data suggests that among 
general population, people with modest elevations in NPs are 
at increased risk for developing cardiovascular morbidity and 
mortality [68-70]. However, for accurate screening of sub 
clinical disease a clear delineation of the optimal cut off val-
ues and understanding of major cardiac (ischemia, arrhyth-
mia) and non cardiac (age, gender, obesity, anemia, renal 
function) sources of variation in NPs in the population is 
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care are considerably lower than for emergency department-
based evaluation of acute dyspnea, and use of these higher 
cut points would be expected to result in reduced sensitivity 
of BNP or NT-proBNP. Indeed, as demonstrated by Tang 
and colleagues [61], the use of a BNP cut point of 100 
pg/mL was associated with a disastrously low sensitivity 
among symptomatic HF patients in a HF/transplant clinic. 
  Among asymptomatic individuals in the community, NPs 
have been investigated for their ability to detect increased 
LV mass and impaired systolic and, or diastolic dysfunction. 
However, their performance relies on the characteristics de-
termined by patient population. In a low risk population, 
lower pretest probability render NPs suboptimal for general 
screening of population [71-74], in addition, screening with 
NP’s may be cost prohibitive. In a study by Rosenfield et al.,
[71] BNP testing was found to be sub-optimal for screening 
patients with pre clinical systolic or diastolic dysfunction. 
Comparable results were reported in the Framingham Off-
spring Study by Vasan et al., [74], who observed suboptimal 
diagnostic accuracy of NPs for detection of mild left ven-
tricular dysfunction (LVSD) (EF<50%) and LV mass espe-
cially among women. However, the diagnostic performance 
improved in women when moderate LSVD was targeted (EF 
<40%).  
  In contrast, use of NPs to screen select populations with 
higher risk for developing HF (including patients with coro-
nary artery disease, hypertension, or diabetes mellitus who 
do not yet demonstrate impaired LV function, hypertrophy, 
or geometric chamber distortion, so called AHA stage A) 
may be advantageous. 
  It has been shown in population studies examining such 
patients that NP levels are generally higher in diabetics, hy-
pertensives as well as those with increased LV mass [75]. 
These higher levels while prognostically relevant [76,77], 
may also be useful to identify those in whom targeted thera-
peutic intervention might be most appropriate. 
  Thus, depending upon the population investigated, there 
have been varying reports on the value of BNP for detecting 
LVSD in general populations (Table 2). Areas under the re-
ceiver operating characteristic (ROC) curve have ranged 
from 0.59 [78] to 0.95 [79], suggesting a potential utility in 
higher-risk, targeted groups, to identify cardiac abnormalities 
and thus trigger further work up and more intensive treat-
ment.  
  From a perspective of modality of use, it is generally felt 
that the value of NP’s for widespread population screening is 
related to their negative predictive value (NPV), rather than 
their positive predictive value (PPV). That is, these assays 
are best used to exclude risk than to identify it. As an exam-
ple, Epshteyn et al. [80] showed that in high risk asympto-
matic diabetic population, BNP levels <39 pg/ml showed a 
high negative predictive value of 91%. In order to determine 
an appropriate BNP level which would preclude the need for 
echocardiography, it was shown that the cutoff point of 20 
pg/mL had an impressive negative predictive value for those 
Table 2.  Use of Natriuretic Peptides for Screening in Low Risk and High Risk Population 
Cohort Type  Optimal Cut off Value  AUC  NPV  PPV 
Low Risk or General Population 
Redfield et al.
(EF <40% or moderate-to-severediastolic dysfunction) 
25.9 pg/mL (BNP)  0.79  N/A  N/A 
Vasan et al.
                         EF 50
                          EF40
45 pg/mL    (BNP) 
50 pg/mL 
51 pg/mL    (BNP) 
50 pg/mL 
M=0.72 
W=0.56 
M=0.79 
W=0.85 
0.93 
0.98 
0.97 
1.00 
0.38 
0.07 
0.22 
0.04 
High Risk or Symptomatic 
Gustafsson F et al.
Systolic DysfunctionEF 0.40 
125 pg/mL (NT-proBNP)  0.87  0.99  0.15 
Faut et al.
Systolic DysfunctionEF 0.40 
40 pg/mL   (BNP) 
150 pg/mL  (NT-proBNP) 
0.79 
0.81 
0.88 
0.92 
0.49 
0.48 
Krishnaswamy P et al.    
Systolic or Diastolic Dysfunction 
48 pg/mL (BNP)  0.95  0.85  0.90 
Lubien E et al.
Diastolic Dysfunction 
62 pg/mL (BNP)  0.91  0.89  0.78 
Mak GS et al.   
Diastolic Dysfunction 
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with systolic dysfunction (96%) or systolic plus diastolic 
dysfunction (100%) [81]. Similarly, for NT-proBNP a cut-off 
value of 125 pg/mL had the sensitivity, specificity, positive 
predictive value, and negative predictive values of 0.97, 
0.46, 0.15 and 0.99, respectively to detect LVSD (EF < 40). 
Area under the ROC curve was 0.87. The application of an 
age-differentiated cut-off value for NT-proBNP (125 pg/mL 
for <75 years old and 450 pg/mL for > 75 years old) did not 
increase diagnostic performance [82].  
  Utility of BNP testing for identifying any structural heart 
disease in addition to LV systolic dysfunction was assessed 
in another study [83] involving general population. In ROC 
analyses, the AUC was suboptimal (0.77; 95% CI=0.74-
0.79) for general screening of structural heart diseases in-
cluding mild left ventricular systolic dysfunction, valvular 
heart disease, hypertensive heart disease, hypertrophic car-
diomyopathy , ischemic heart disease and lone atrial fibrilla-
tion. This efficacy was improved when select groups with a 
high prevalence of heart disease were considered. For in-
stance, those older then 65 (men, AUC = 0.88; women, AUC 
= 0.83) as well as those with hypertension or diabetes (men, 
AUC = 0.85; women, AUC = 0.83). Similar results were 
reported earlier in another Japanese study where a plasma 
BNP level of 40 pg/ml had a sensitivity of 85% and a speci-
ficity of 92% for heart disease detection. AUC for BNP was 
significant 0.94 and a plasma BNP level of 13 pg/ml or less 
had a 100% NPV for heart disease [84].  
  In patients with isolated diastolic dysfunction, NPs may 
be elevated and may reflect the severity of dysfunction [85-
89]. Moreover, BNP and NT-proBNP are elevated in those 
with mild diastolic dysfunction and correlate with increased 
filling pressures during exercise [90,91]. In a study by Lu-
bien et al. [86], the area under the ROC curve for BNP to 
detect any diastolic dysfunction was 0.92 (0.87–0.95; 
p<0.001); patients with restrictive-like filling patterns on 
echocardiography had the highest BNP levels (408±66 
pg/mL) and AUC =0.97 (Fig. 1 ). Importantly, however, 
while NP levels are unable to differentiate systolic vs. dia-
stolic dysfunction [89] but in patients with symptoms of HF 
and normal systolic function, NP values may useful to pre-
dict diastolic abnormalities.  
  Importantly, even in the absence of overt HF, modest 
elevations in plasma NPs levels are prognostically meaning-
ful in population-based testing. In a population-based pro-
spective study of 1991 subjects without apparent heart fail-
ure both BNP and NT-proBNP were predictive of mortality 
after a median follow up of 5.6 years even after adjustment 
for clinical and echocardiographic abnormalities including 
left ventricular hypertrophy and diastolic dysfunction [92]; in 
this analysis, NT-proBNP was clearly superior to BNP for 
prognostication. In another prospective study of 3346 per-
sons without heart failure, elevated BNP values above the 
80th percentile (20 pg/mL for men and 23 pg/mL for 
women) were associated with multivariable-adjusted hazard 
ratios of 1.62 for death (P=0.02), 1.76 for a first major car-
diovascular event (P=0.03), 1.91 for atrial fibrillation (P= 
0.02), 1.99 for stroke or transient ischemic attack (P=0.02), 
and 3.07 for heart failure (P=0.002) [40]. Similarly, in an-
other study of general population, McDonagh et al., showed 
that BNP was an independent predictor of 4-year all-cause 
mortality [93].  
  Overall, studies would thus suggest that the optimal ap-
proach for applying NP testing to detect HF or prognosticate 
in general populations is to select the target population care-
fully, with superior performance observed among patients 
with a higher baseline risk (such as hypertensives or diabet-
ics). As well, unlike for acute HF, where higher decision 
limits are used, the cut off value for outpatient testing for 
BNP is 20-40 ng/mL and for NT-proBNP it is 100-150 ng/L. 
Values below these cut-points exclude the presence of car-
diac abnormalities with a high NPV; values above these cut-
points suggest further evaluation is necessary but do not ab-
solutely guarantee the presence of cardiac structural abnor-
malities. 
Diagnostic Evaluation in Symptomatic Patients 
  In symptomatic primary care patients, both BNP and NT-
proBNP serve as excellent tools for excluding HF based on 
their excellent negative predictive values [94-100]. In pa-
tients with symptoms suggestive of HF, Cowie et al. [94] 
investigated the value of BNP and showed that a cut-off 
value of 22 pmol/L for BNP could rule out the diagnosis of 
HF with high NPV of 98%. Similarly, in a prospective, ran-
domized controlled trial involving 305 patients with symp-
toms of dyspnea and/or peripheral edema, NT-proBNP 
measurement significantly improved the diagnostic accuracy 
by a general practitioner over and above clinical review by 
correctly ruling out heart failure [95]. In another study [96] 
(Fig. 2), NT-proBNP levels identified those with symptoms 
of heart failure and LVEF <40% among general population 
with a sensitivity of 92%, a specificity of 86%, negative pre-
Fig. (1). ROC curve comparing sensitivity and specificity of BNP 
and echocardiographic diagnosis of various diastolic filling pat-
terns. Patients with abnormal systolic function were excluded. AUC 
is significant (P<0.001) for each diastolic filling abnormality 
vs. patients with normal systolic function (patients with other dia-
stolic filling abnormalities excluded in each analysis). Lubien E 
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dictive values of 100% and area under the curve of 0.94. 
Similarly in another study [97] both BNP and NT-proBNP 
had excellent negative predictive values for exclusion of HF 
in patients with clinical suspicion of HF; in this study, a BNP 
at a cut-off of 40 pg/ml had a NPV of 88%, and an NT-
proBNP of 150 pg/ml gave a NPV of 92%. 
Fig. (2). Receiver operating characteristic (ROC) curves for the 
ability of NT-proBNP to diagnose systolic HF and LVEF <50%/<
45%/< 40%/< 35%, respectively. For the diagnosis of heart failure 
<40, NT-proBNP = 106.7 pmol/l had sensitivity/specificity 0.92/ 
0.86, positive predictive value /negative predictive value 0.11/1.00 
and AUC = 0.94 Groenning BA et al. [96].
  In a meta analysis involving 19 studies, 22 populations, 
authors suggested that in a low risk population appropriate 
use of NPs can help reduce the demands of echocardiogrpay 
and cardiac referrals [99]. In a recent study [101], NT-
proBNP use among symptomatic patients in general practice 
was found useful for cost-effective exclusion of the diagno-
sis of heart failure (HF). 
  Thus, in the presence of symptoms, a general recommen-
dation would be to apply NP testing with the goal to exclude 
HF. Using cut-points of 20-40 pg/mL for BNP and 125-150 
ng/L for NT-proBNP provides excellent NPV in this regard. 
Results above these levels do not necessarily confirm HF, 
but suggest that further evaluation is necessary (Fig. 3). Im-
portantly, age exerts a significant effect on NP concentra-
tions, thus, lower cut-points might be useful for younger 
patients, while higher cut-points (e.g. an NT-proBNP of 300-
450 ng/L) might provide superior NPV for elders. The opti-
mal cut-points for BNP in elders remain unclear. 
Outpatient Measurement of NPs in Patients with Estab-
lished HF 
  The longitudinal clinical assessment of stability (and 
hence prognosis) in HF is difficult because of the lack of 
strong predictors of mortality or morbidity. Plasma natri-
uretic peptide levels increase in patients with symptomatic 
HF in proportion to the severity of disease and correlate with 
several indices of heart failure such as the New York Heart 
Association (NYHA) functional class, hemodynamics, left 
ventricular ejection fraction and filling pressure [102-104]. 
In patients with chronic HF, plasma BNP and NT-proBNP 
predict functional capacity and exercise tolerance [105-108]. 
In terms of mortality NPs predict mortality across the entire 
spectrum of HF patients, in those patients with advanced 
disease as well as those with minimally symptomatic left 
ventricular dysfunction [109,110]. In fact, among plasma 
levels of ANP, BNP, cGMP, and norepinephrine and clinical 
and hemodynamic parameters, only high levels of plasma 
BNP (P<.0001) and pulmonary capillary wedge pressure 
(P=.003) were significant independent predictors of the mor-
tality in patients with HF by Cox proportional hazard analy-
sis [109]. Accordingly, a recent systematic review suggested 
that BNP is a strong prognostic indicator at all stages of 
disease and seems to be a better predictor of survival than 
many traditional factors, such as NYHA class, serum creatin-
ine, and even left ventricular ejection fraction [110]. Moreo-
ver, BNP and NT-proBNP, were independently related to 4-
year mortality in patients with severe heart failure receiving 
established heart failure therapy including angiotensin-
converting enzyme inhibitors and beta-blocker therapy [111].  
  While elevated baseline values of NPs are predictive of 
poorer outcomes, the prognostic value of the changing levels 
of BNP and NT-proBNP levels measured during treatment 
could be even more meaningful [112-115]. Furthermore, 
patients whose BNP values fail to fall in response to treat-
ment tend to be at particularly high risk of death or a cardio-
vascular event [112,114,116,117]. Anand et al. [112] ana-
lyzed the significance of change in BNP over time from 
baseline to 4 and 12 months. While higher baseline values 
were predictive of morbidity and mortality, a further increase 
in BNP values over time led to further incremental rise in 
risk. On the other hand patients with the greatest percent 
decrease in BNP from baseline to 4 and 12 months had the 
lowest morbidity and mortality. 
  Because lower levels of BNP or NT-proBNP are associ-
ated with better clinical outcome, and patterns of NP concen-
trations appear to be more prognostic than single measure-
ments, it is logical to assume that titration of treatment to 
achieve lower NPs levels may be advantageous. The logic 
behind this concept is that concentrations of NPs decrease 
following institution or intensification of several established 
therapies of HF; among these agents are diuretics, angio-
tensin converting enzyme (ACE) inhibitors, angiotensin re-
Fig. (3). A suggested algorithm for evaluation of symptomatic pa-
tients. Clinical evaluation should be supplemented with natriuretic 
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ceptor blockers (ARB),  blockers, spironolactone, and ne-
siritide [29-52].  
  While levels of BNP and NT-proBNP fall parallel to the 
fall in filling pressures with institution of diuretics and vaso-
dilators [29-36], it is interesting to note that initiation of non-
loop diuretics with relatively modest diuretic effects such as 
spironolactone may lead to substantial acute and chronic 
reductions in BNP and NT-proBNP [38-42]. The acute fall 
may be related to a diuretic effect followed by more signifi-
cant reductions in BNP or NT-proBNP related to the sug-
gested benefits of spironolactone on ventricular remodeling 
[43]. Similarly, ACE inhibitors besides decreasing filling 
pressures [32-36], in addition they may have an anti remod-
eling related effect on natriuretic peptide levels. The re-
sponse to -blockers is more complex. Introduction of me-
toprolol in stable mild HF is associated with an initial rise in 
NT-proBNP levels that is related to its secretion (or clear-
ance) but is not due to clinical decompensation [44, 45]. 
Longer-term following -blocker therapy initiation or ad-
justment, levels of natriuretic peptides fall, paralleling 
changes in LV remodeling [45, 46]. The response of NT-
proBNP to carvedilol (and other vasodilator -blockers) may 
be different from metoprolol, with an initial fall in natriuretic 
peptide levels [47-50]; since there were significant differ-
ences in the stages of HF of the studies comparing effects of 
-blockers, these findings may be more due to different re-
sponses in NT-proBNP at different stages of HF, rather than 
heterogeneity in response to different agents.  
  The clinical benefit of titrating therapy according to NP 
levels was tested in a landmark study by Troughton et al.
[118] patients with decompensated HF and ejection fractions 
of <40% were recruited to test the hypothesis that any treat-
ment that decreases NT-proBNP levels to <200 pmol/L (ap-
proximately 1700 ng/L) would reduce cardiac events. Their 
results showed that NT-proBNP guidance resulted in fewer 
combined heart failure decompensation, hospitalization and 
mortality events (19 versus 54, p=0.02). More recently, find-
ings supportive of natriuretic peptide guided HF therapy in 
context of a more contemporary HF regimen were demon-
strated in the recently published STARS-BNP study [119]. 
In this multicenter study, 220 patients with NYHA func-
tional class II–IV heart failure were randomized to BNP and 
clinically guided treatment. Therapies adjusted to achieve a 
BNP (target value<100 ng/L) resulted in more frequent 
changes 134 versus 66 in clinical group (p < 0.05); with all 
types of HF drugs changed more frequently in the BNP 
group. After a median 15 months follow up, the primary 
composite end point (unplanned hospital stays for heart fail-
ure or death related to heart failure) was observed in 25 of 
110 (24%) in the BNP group versus 57 of 110 (52%) in the 
clinical group, p < 0.001). Similarly, the STARBRITE study 
assessed the impact of targeting treatment to achieve an 
individualised BNP target during short-term follow-up [120]. 
While this strategy did not significantly reduce the number 
of days alive and out of hospital it did result in more optimal 
use of ACE inhibitor and -blocker therapy, while diuretics 
were less likely to be increased.  
  The effect of guiding treatment to achieve targeted levels 
of NPs is currently being tested in several larger randomised 
trials. Methods papers have been published for the 
BATTLESCARRED [121] and TIME-CHF [122] and many 
other studies are examining the role of BNP or NT-proBNP 
guidance for heart failure therapy. These studies will assess 
the effect of this strategy in large cohorts.  
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